Loading clinical trials...

A Study of a Decision Tool for People Considering Breast Reconstruction Surgery | Clinical Trials | Clareo Health

RECRUITINGNA

A Study of a Decision Tool for People Considering Breast Reconstruction Surgery

Breast Reconstruction Decision Aid (RECONJOINT)

NCT07335354•Memorial Sloan Kettering Cancer Center

Summary

The purpose of this study is to find out whether it is practical (feasible) to do a larger study looking at the effectiveness of the Breast Reconstruction Decision Aid Tool (RECONJOINT) for breast reconstruction surgery.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Focus Group Participants
•A diagnosed genetic predisposition to breast cancer or a diagnosis of ductal carcinoma in situ or any invasive cancer confirmed through review of the medical record
•≥18 years old
•Considering post-mastectomy breast reconstruction
•RCT Participants (Patients)
•A diagnosed genetic predisposition to breast cancer or a diagnosis of ductal carcinoma in situ or any invasive cancer confirmed through review of the medical record
•≥18 years old
•Considering post-mastectomy breast reconstruction
•Have an appointment scheduled for consultation with a plastic surgery provider
•RCT Participants (Physicians)
+1 more criteria

Exclusion Criteria

•Focus Group Participants
•Not considering post-mastectomy breast reconstruction
•Non-English proficiency
•RCT Participants (Patients)
•Not considering postmastectomy breast reconstruction
•Recurrent or metastatic breast cancer
•Male sex
•Non-English proficiency
•RCT Participants (Physicians)
•Does not provide breast reconstruction care at least 50% of the time
+1 more criteria

Locations (8)

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen

Montvale, New Jersey, United States

Memorial Sloan Kettering Commack

Commack, New York, United States

Memorial Sloan Kettering Westchester

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Memorial Sloan Kettering Nassau

Rockville Centre, New York, United States

Duke Cancer Institute (Data collection only)

Durham, North Carolina, United States

Key Dates

Start Date

January 5, 2026

Primary Completion Date

January 5, 2029

Completion Date

January 5, 2029

Last Updated

January 13, 2026

Enrollment

131

ESTIMATED participants

Conditions

Breast Cancer

Interventions

RECONJOINT

OTHER

Contacts

Evan Matros, MD

CONTACT

646-608-8044 matrose@mskcc.org

Carrie Stern, MD

CONTACT

646-608-8048 sternc2@mskcc.org

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

NCT05372640

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+6 more

View study

RECRUITINGPHASE2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 13, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of a Decision Tool for People Considering Breast Reconstruction Surgery

Inclusion Criteria

Exclusion Criteria

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer